The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 26, 2022
Filed:
Feb. 08, 2018
Applicant:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Inventors:
James Bradner, Weston, MA (US);
Justin Roberts, Cambridge, MA (US);
Behnam Nabet, Boston, MA (US);
Georg Winter, Vienna, AT;
Andrew J. Phillips, Cambridge, MA (US);
Timothy P. Heffernan, Cambridge, MA (US);
Dennis Buckley, Jamaica Plain, MA (US);
Assignee:
DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/52 (2006.01); A61P 37/06 (2006.01); A61K 35/17 (2015.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 495/04 (2006.01); C07D 495/14 (2006.01); C07J 43/00 (2006.01); C07K 14/535 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 9/90 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
A61K 38/52 (2013.01); A61K 35/17 (2013.01); A61P 37/06 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 495/04 (2013.01); C07D 495/14 (2013.01); C07J 43/003 (2013.01); C07K 14/535 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 9/90 (2013.01); C12Y 502/01008 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01);
Abstract
This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.